|
Expression of EBAG9 and 22-1-1 on cancer cell lines. |
|||
| Cell line |
Origin |
22-1-1 expression Flow cytometry |
EBAG9 expression Immunoblot |
|
|
|||
| MCF-7 |
breast carcinoma |
++ |
+++ |
| K562 |
chronic myelogenous leukemia |
- |
+++ |
| Jurkat |
T cell leukemia |
+++ |
+++ |
| Colo-205 |
colorectal carcinoma |
- |
+++ |
| SiSo |
cervix carcinoma |
+ |
+++ |
| CAL-51 |
breast carcinoma |
- |
+++ |
| T-47D |
breast carcinoma |
- |
+++ |
| ZR-75-1 |
breast carcinoma |
- |
+++ |
| HBL-100 |
breast carcinoma |
- |
+++ |
| U-266 |
multiple myeloma |
- |
++ |
| CaCo-2 |
colon carcinoma |
- |
++ |
| MDA-MB-461 |
breast carcinoma |
- |
+ |
| HEK293 A |
embryonal kidney |
- |
+ |
| U-373 |
glioblastoma-astrocytoma |
- |
+ |
| L-1236 |
Hodgkin's lymphoma |
- |
+ |
| H-184 A1 |
normal breast |
- |
+ |
| SW-480 |
colon carcinoma |
- |
+ |
| MDA-MB-468 |
breast carcinoma |
- |
+ |
|
Expression of antigen on the cell surface was determined by incubation with 22-1-1 antibody and analysed by flow cytometry. Expression of EBAG9 was determined by immunoblot using the anti-EBAG9 serum. (+++, very high expression, ++, high expression, +, intermediate expression, -, no expression). | |||
Reimer et al. BMC Cancer 2005 5:47 doi:10.1186/1471-2407-5-47 |
|||